Beam Therapeutics Inc. (BEAM) Form 10-Q — Aug 4, 2026
Beam Therapeutics reported a net loss of $217.0 million for the six months ended June 30, 2026, compared to a loss of $210.5 million in the prior year period, while license and collaboration revenue more than doubled to $32.2 million. The revenue increase was driven by a $25 million milestone payment from Eli Lilly and recognized revenue from the Apellis collaboration. The company ended the quarter with approximately $1.15 billion in cash, cash equivalents, and marketable securities, which it expects will fund operations for at least the next 12 months.
Key figures
- Revenue
- 32228000
- Total Debt
- 100258000
- Cash Position
- 1152927000
- Rd Expenses
- 199620000
Price after filing
Close on the filing date to close N calendar days later (from $26.49). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.